Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)

The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin-Sun, Shin, Joon-Han, Hong, Taek-Jong, Seo, Hong-Seog, Shim, Wan-Joo, Baek, Sang-Hong, Jeong, Jin-Ok, Ahn, Youngkeun, Kang, Woong-Chol, Kim, Young-Hak, Kim, Sang-Hyun, Hyon, Min-Su, Choi, Dong-Hoon, Nam, Chang-Wook, Park, Tae-Ho, Lee, Sang-Chol, Kim, Hyo-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993275/
https://www.ncbi.nlm.nih.gov/pubmed/27574399
http://dx.doi.org/10.2147/DDDT.S112873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993275/
https://www.ncbi.nlm.nih.gov/pubmed/27574399
http://dx.doi.org/10.2147/DDDT.S112873

Ejemplares similares